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“If we keep patients out of the picture,  
we will never get the full story about medicines safety.” 
(Uppsala Report 65, April 2014)  
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ABSTRACT 
 
Background: New Pharmacovigilance legislation allows patients to report adverse drug reactions 
(ADRs) directly to competent authorities in all European Union (EU) member states. Patient 
reporting is available in Portugal since July 2012. In 2013, the National Pharmacovigilance System 
(SNF) had received 3461 spontaneous ADR reports, of which only 1.4% (n=50) were reported by 
patients. Underreporting remains a reality in Portugal, although patient reporting could be one of 
the measures to reduce the rate of underreporting by healthcare professionals (HCP). 
Objectives: The aim of this study was to describe the attitudes and knowledge of the patients 
regarding spontaneous reporting and the reasons and opinions that can influence patients ADR 
underreporting. 
Methods: A descriptive-correlational study was performed looking for patients’ attitudes and 
knowledge regarding spontaneous reporting. A 6-months survey was conducted from June to 
November 2013 in general adult patients from a community pharmacy in Coimbra, Portugal, that 
used prescribed medicines or OTC-drugs. Attitudes and opinions were surveyed in a closed-
answer questionnaire using a Likert scale. Incomplete questionnaires and answers from 
healthcare professionals were excluded from data analysis. The data were analyzed using 
descriptive statistics, χ2 tests and Spearman’s correlation coefficients. 
Results: A total of 1084 questionnaires were collected with a response rate of 81,1% and 948 
completed questionnaires were selected for analysis. Of the respondents, 44.1% never heard 
about SNF. Younger people and those with a higher education were significantly more likely to be 
aware of SNF. Only 1 patient had previously reported an ADR directly to SNF. Reporting ADRs 
indirectly through an HCP was preferred by 62.4%. The main reasons for patients reporting 
spontaneous ADR would be the severity of the reaction (81,1% agreed or strongly agreed) and 
worries about their own situation (73,4% agreed or strongly agreed). Only weak and moderate 
correlations were found between studied statements. 
Conclusions: Patients are most likely to do a spontaneous report about a severe reaction or if 
they are worried about the symptoms. Tailored and proactive information on ADR reporting and 
educational interventions on patients could increase the number of reports from patients in 
Portugal. 
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RESUMO 
 
Background: A nova legislação em Farmacovigilância permite aos pacientes notificarem reacções 
adversas a medicamentos (RAM) diretamente às autoridades competentes, em todos os estados-
membro da União Europeia (EU). Em Portugal, a notificação por pacientes está disponível desde 
Julho de 2012. Em 2013, o Sistema Nacional de Farmacovigilância (SNF) recebeu 3461 notificações 
espontâneas de RAM, das quais apenas 1.4% (n=50) foram feitas diretamente por pacientes. Em 
Portugal, a sub-notificação continua a ser uma realidade, esperando-se que as notificações dos 
pacientes possam ser uma medida capaz de contribuir para a redução da sub-notificação dos 
profissionais de saúde. 
Objectivo: O objectivo deste estudo foi descrever as atitudes e conhecimento dos pacientes no 
que diz respeito à notificação espontânea de RAM e as razões e opiniões que podem influenciar a 
sub-notificação de pacientes. 
Métodos: Foi realizado um estudo descritivo-correlacional para descrever as atitudes e 
conhecimento dos pacientes no que diz respeito à notificação espontânea de RAM. O período de 
estudo foi de Junho a Novembro de 2013, sendo a amostra composta por consumidores de 
medicamentos de uma Farmácia Comunitária em Coimbra, Portugal. Foram questionados acerca 
das atitudes e opiniões com recurso a um questionário de resposta fechada utilizando a escala de 
Likert. Questionários incompletos ou de profissionais de saúde foram excluídos da análise de 
dados. Os dados foram analisados com recurso à estatística descritiva, teste χ2 e coeficientes de 
correlação de Spearman. 
Resultados: Foram recolhidos 1084 questionários, obtendo-se uma taxa de resposta de 81,1%. 
Foram selecionados 948 questionários para análise. 44.1% dos pacientes nunca ouviram falar do 
SNF. Os mais jovens e com maior nível educacional estão significativamente mais conscientes da 
existência do SNF. Apenas um paciente notificou anteriormente uma RAM diretamente ao SNF. 
62,4% dos pacientes preferem notificar RAM’s através de um profissional de saúde. As razões 
principais para fazer uma notificação espontânea foram a severidade da reacção (81,1%) e a 
preocupação pela sua situação (73,4%). Foram encontradas apenas correlações moderadas ou 
ligeiras entre as razões e opiniões estudadas. 
Conclusão: Os pacientes são mais propensos a fazer uma notificação espontânea se a reacção for 
severa ou se estiverem preocupados com a sua situação. Formação e informação proactivas e 
personalizadas acerca da notificação de RAM pode aumentar o número de notificações por 
pacientes, em Portugal. 
 
PALAVRAS-CHAVE 
Farmacovigilância, Notificação por pacientes; Notificação de RAM; Conhecimentos e Atitudes  
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INTRODUCTION 
This research, “Are patients ready to take part in Pharmacovigilance System? – a 
Portuguese preliminary study concerning ADR reporting”, was submitted to the ESTESC – 
Coimbra Health School for fulfillment of the requirements for the Master degree in 
Pharmacy, held under the scientific supervision of Florence P.A.M. van Hunsel, PharmD 
PhD MEpi (Netherlands Pharmacovigilance Centre - Lareb) and co-orientation of João José 
Joaquim, MSc (Adjunct Professor of Pharmacy Department - Coimbra Health School).  
 
AIM OF THE STUDY 
The aim of the present study is to gain insight into the attitude and behavior of patients in 
Portugal with respect to the reporting of ADRs. Therefore, our main research questions 
are: “Which motives for reporting adverse drug reactions are present in a large group of 
patients in Portugal?” and “What could be the next steps to bring patients to active 
Pharmacovigilance?”. 
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1. BACKGROUND 
This chapter gives a review of the literature concerning Pharmacovigilance, its history, 
new legislation, and the Portuguese reality and overview on contribution of the patient 
reporting in Pharmacovigilance. 
 
1.1. INTRODUCTION IN PHARMACOVIGILANCE 
Pharmacovigilance can be defined as “the science and activities related to the detection, 
assessment, understanding and prevention of adverse effects or any other medicine-
related problems”.(1) The main objectives of pharmacovigilance are preventing harm from 
adverse reactions in humans arising either from the use of authorized medicinal products, 
within or outside the terms of marketing authorization, or from occupational exposure; 
and promoting the safe and effective use of medicinal products, through providing timely 
information about the safety of medicinal products to patients, healthcare professionals 
(HCPs) and the public.(1) 
Lazarou(2) cited the definition of adverse drug reactions (ADRs), based on the World 
Health Organization (WHO),(3) as “any noxious, unintended, and undesired effect of a 
drug, which occurs at doses used in humans for prophylaxis, diagnosis, or therapy”. This 
definition excludes therapeutic failures, intentional and accidental poisoning (i.e., 
overdose), and drug abuse. Also, this does not include adverse events due to errors in 
drug administration or noncompliance (taking more or less of a drug than the prescribed 
amount). However, according to the new definition proposed in the guideline on new 
good pharmacovigilance practices, which is a final result of the 2010 pharmacovigilance 
legislation(4) which will be discussed ahead, “adverse reactions may arise from use of the 
product within or outside the terms of the marketing authorization or from occupational 
exposure. Conditions of use outside the marketing authorization include off-label use, 
overdose, misuse, abuse and medication errors”.(1, 5) 
Today, its globally accepted that ADRs are a public health problem and have a significant 
clinical impact related to morbidity and mortality which results in an increased use of 
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health services in developed countries.(2, 6) ADRs are responsible for about 6,5% of all 
hospital admissions and many of them were judged preventable(6, 7) and about 2-3% of 
those patients admitted with an ADR died as a result.(6, 8) Furthermore, ADRs may occur in 
6-20% of patients admitted to hospitals, increasing the hospitalization period, thus 
increasing the costs associated with health care.(9) 
ADRs have a direct impact on National Health Services (SNS) costs and even an indirect 
impact on patients and family in economic, social and psychological way.(10) The average 
treatment costs of a single ADR were valued up to several thousand euros,(6) that could 
be even greater when indirect costs are analysed, like patient hospitalization duration – 
length-of-stay. ADRs can have a significantly impact on hospitals’ budget and, 
consequently, can lead to important charges to healthcare systems.(9) 
Because not all adverse drug reactions of a product are known once it’s granted 
marketing authorization, pharmacovigilance is needed to learn more about possible 
harmful effects of a drug. According to WHO,(1) pharmacovigilance plays a vital role in 
ensuring that healthcare professionals, such as physicians and pharmacy professionals, 
together with the patient, have enough information to make an educated decision when 
it comes to choosing a drug for treatment.(11) 
The information gathered during the pre-marketing phase of a medical drug is inevitably 
limited and incomplete with regard to possible adverse reactions,(12, 13) although its safety 
profile and efficacy were previously studied. Effectively, the identification of adverse 
reactions, during the experimental phase, is limited, since the exposed population has 
particular characteristics, since this is a selected population, contrasting with the 
population that is exposed to the drug, in a real context, after marketing. During clinical 
trials, individuals with concomitant diseases and medication, or in specific conditions 
(pregnant, lactating infants, polymedicated patients, elderly and children) are excluded or 
underrepresented. In addition, the small number of subjects and the time spent in clinical 
trials are usually insufficient to detect certain events with lower incidence or which occur 
over the long term, that are difficult to detect during the phases of clinical trials that 
precedes the marketing of the product.(14) 
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Relevant and unidentified ADR can occur after marketing authorization and  
pharmacovigilance in that phase is of a capital importance since the drug is used in a real-
life context and in a large and heterogeneous population, with the majority of unknown 
ADRs effectively being detected this phase.  
For an effective pharmacovigilance, the creation of a pharmacovigilance network 
between countries to allow exchange of information is necessary.(12) At the time of 
marketing authorization, the risk-benefit ratio to medicinal products is judged positive for 
the target population.(13) However, not all actual or potential risks have been identified, 
becoming essential to introduce risk management plans (RMPs) in order to identify, 
characterize, prevent or minimize risk relating to medicinal products, including the 
assessment of the effectiveness of those interventions.(11, 13) The concept of risk 
management should also consider the combination of information on multiple risks with 
the aim of ensuring that the benefits exceed the risks by the greatest possible margin for 
the individual patient.(13) 
 
1.1.1. The start and further organization of pharmacovigilance systems 
The most well-known example of an ADR recognized after marketing approval occurred in 
1961: the thalidomide tragedy has originated the birth of approximately 10,000 children 
with phocomelia. This tragic event led to authorities and healthcare professionals being 
engaged in the development of different methodologies to detect and study the adverse 
effects of medicines and the creation of structures suitable for early detection.  
In 1968, the first pilot project for the creation of an international system of 
pharmacovigilance through a "Programme for International Adverse Event Monitoring" 
was started, based on the experience and essential elements collected in the 10 countries 
who signed the program and who immediately created their National Pharmacovigilance 
Centres, networking with WHO. 
When the program was evaluated in 1970, the World Health Assembly concluded that it 
should be permanent, being installed, in Uppsala, Sweden, in 1978 - initially under the 
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designation "WHO Collaborating Centre for International Drug Monitoring" and today 
called as "Uppsala Monitoring Centre (UMC)".  
The main functions of the WHO Programme for International Drug Monitoring include the 
“identification and analysis of new adverse reaction signals from the case report 
information submitted to the National Centres, and sent from them to the WHO 
database” and “exchange information between WHO, UMC and National 
Pharmacovigilance Centres”. 
Since 1978, UMC has managed primary aspects of expanding worldwide 
pharmacovigilance network of more than 130 countries, nowadays. 
 
1.1.2. Spontaneous reporting of ADRs 
According to WHO, spontaneous ADR reporting is defined by “a regional or country-wide 
system for the reporting of suspected adverse drug reactions”. Existing 
pharmacovigilance systems have proven to be useful in identifying patient safety issues, 
although there is scope for optimizing and improving their use.(10) Thus, this is the primary 
method in pharmacovigilance and it is useful to picking up signals of relatively rare, 
serious and unexpected adverse reactions.(12, 15) Spontaneous reporting is generally used 
for signal detection purposes and in publications about ADR.(10) This is particularly 
important for rare or serious reactions to established drugs, or reactions to newly 
marketed medicines where knowledge about their safety profile is based upon relatively 
limited exposure information obtained during premarketing clinical trials. A number of 
important signals of ADRs have been identified through spontaneous reporting.(16) 
Voluntary ADR reporting is one of the most versatile pharmacovigilance systems, 
because, among other advantages, it covers the entire population as well as all drugs 
throughout their commercial life,(7) being also a method that provides the highest volume 
of information with relatively lower maintenance cost than other Pharmacovigilance 
methods.(15) 
In fact, spontaneous reporting of ADRs is the most common method used in 
Pharmacovigilance, and remains one of the most effective methods to detect new, 
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unusual and serious drug reactions;(17) spontaneous reporting has been the primary post-
marketing safety evidences source, that contribute to the early identification and 
evaluation of the drug safety issues, that could result in different regulatory actions such 
as product withdrawal, continued monitoring,  product labelling changes or new 
medication guide-related communication, among others.(18) The monitoring of adverse 
drug reactions through pharmacovigilance is vital to patient safety.(17) 
Despite of this, ADRs are estimated as one of the major causes of hospital admissions and 
death(6) – only around 5 to 6% of all adverse reactions are reported.(19) The success or 
failure of any spontaneous reporting system depends on the active participation of 
reporters.(1) Healthcare professionals have been the major providers of case reports of 
suspected ADRs;(20, 21) although, in recent years, in some countries, such as United 
Kingdom (UK), Denmark and The Netherlands, systems for direct reporting of suspected 
adverse reactions by patients have been initiated and the impact of direct patient 
reporting in these countries has been positive, since it facilitates a better understanding 
of consumer perspectives.(22, 23) Patient reporting is defined as “users of drugs (or their 
parents or carers) reporting suspected ADRs directly to a spontaneous reporting 
system”.(24, 25) However, there has been some discussion on the true value of direct 
reporting by patients. The perceived advantages and possible drawbacks of patient 
reporting of ADRs are discussed in Chapter 1.3 on the Patients’ role in active surveillance.  
 
1.1.3. The introduction of patient reporting in guidelines and legislation 
The importance of direct patient reporting has been highlighted by new European 
legislation on pharmacovigilance. The legislation guides member states to take all 
appropriate measures to encourage patients to report suspected ADRs to the national 
authorities. Member states should also facilitate patient reporting through the provision 
of alternative reporting formats in addition to web-based formats.(4) The aim of the 
legislation is to improve the participation of patients in the decision-making process and 
to resolve the lack of a clear legal basis for patient reporting across the European Union 
(EU).(26) 
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Allowing patients to report adverse drug reactions directly to the competent authorities is 
now seen by the European Commission as a way to improve pharmacovigilance and 
reduce underreporting. Patients’ contribution still represents a relatively small 
percentage of total reports in most countries within the EU.(22, 27, 28) The number of 
countries who encourage patients to report ADRs has increased and a guideline has been 
developed for setting up patient reporting systems. Most of EU countries have very 
recently started with reporting systems for patients, mostly created by imposition of 
international guidelines, so the amount of reports received from patients is very low and 
has weak significance in earlier detection of ADR in many countries. However, feedback 
from countries in which systems have been implemented for a longer period is quite 
positive.(10) For the pilot countries worldwide we can highlight the United States of 
America (USA) and Canada, that have started consumer reporting schemes in the 60’s and 
collects a huge number of reports every year. In 2009, USA and Canada had collected, 
respectively 57% and 32,3% for all reports, directly from patients.(10) More recent pilot 
studies were launched in Europe in The Netherlands (2003), Denmark (2003) and the UK 
(2005) and more recently in other countries.(10) In these countries, in 2009, about 15-30% 
of reports were collected directly from patients. However, the increase in quantity of the 
number of reports received should be reflected in an increased quality and faster signal 
detection. The quality of patient reports appears to be similar to that of healthcare 
professional reports.(29) 
However, little formal evaluation has been undertaken of existing patient reporting. The 
World Health Organization focuses on planning and implementing adverse drug reaction 
systems for the general public and will probably make an important contribution to 
pharmacovigilance strategies.(30, 31) The new WHO guidance(30) provides comprehensive 
advices to implement a well-organized and effective consumer reporting system and it is 
particularly opportune for European Union countries, which are now required to accept 
consumer reports by new EU-wide legislation that came into force in July 2012.(4) 
The new European legislation about Pharmacovigilance(4) is the biggest change in the 
human medicines regulation in the EU since 1995. The European Medicines Agency (EMA) 
is responsible for implementing the new legislation. The new Pharmacovigilance 
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legislation will allow patients to report ADRs directly in all EU member states. Suspicions 
of ADR may be reported online by HCPs and patients through a platform that is currently 
under development in several countries: the introduction of online reporting in Portugal 
is being progressively implemented.(24) It also entails a revision of the definition of 
“adverse drug reaction” bringing to “any harmful effects caused by medications”. 
 
1.2. PHARMACOVIGILANCE IN PORTUGAL 
In contrast to what happened in several European countries, until the early 90s, 
pharmacovigilance was not implemented in Portugal.(32) The National Pharmacovigilance 
System (SNF) was created centrally in 1992a, and has an essential role in the ongoing 
evaluation of the benefit/risk balance of medicines.(33) The national pharmacovigilance 
system is a key tool for monitoring and ensuring the safety of patients, with a view to the 
protection of public health. Since 1999, a reorganization occurred and the SNF has 
become a decentralized system:(33) regional centres have been created to collect 
suspected reports of ADRs from healthcare professionals and to encourage reporting, 
involving universities to promote their scientific and technical expertise and spread the 
system. Actually, the SNF is coordinated by the INFARMED, IP – (National Authority of 
Medicines and Health Products), and composed by four Regional Pharmacovigilance Units 
(URF) that covers the entire region of continental Portugal: North Pharmacovigilance Unit 
(UFN), the Pharmacovigilance Unit of Centre region (NFC), the Pharmacovigilance Unit of 
Lisboa and Vale do Tejo (UFLVT) and the South Pharmacovigilance Unit (UFS). Each Unit 
promotes training activities among reporters and evaluates the ADR reports occurring in 
their respective geographical areas. The SNF monitors the safety of medicines with 
marketing authorization in the domestic market, assessing any problems with ADR and 
implementing security measures whenever necessary. 
On 30th August 2006, the Decree-Law No 176/2006 was approved,(34) which unifies the 
main laws of the medicinal product area and put together all legislation on 
Pharmacovigilance.(35) This document defines the Portuguese National Pharmacovigilance 
                                                          
a The creation of the SNF in 1992 was announced by the Decree -Law No. 72/91 of 08
th
 February and Order 
No. 107/92 of June 27. 
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System as we know it today and all of his tasks, of which we can highlight the collection 
and review of spontaneous reports and detection of previously unknown adverse 
reactions as well as assessing the impact of already known reactions. All reports are 
evaluated and analysed in order to generate a signal or warning of the occurrence of a 
problem related to a drug effect.(34) 
Encourage HCPs to report has been one of the major challenges of the SNF. Physicians 
were represented since the beginning of the SNF. Pharmacists were incorporated into 
pharmacovigilance in 1995, and reported in collaboration with physicians, who validated 
their reports until 1997.(7) From 1997, pharmacists were allowed to report directly to 
health authorities, independently of physicians.(7, 36) Nurses are participating in the SNF 
since 2000, accounting for the majority of adverse reactions to vaccines. 
From 2009, it became possible for other classes of healthcare professionals to report, 
including pharmacy technicians (PhT) and nutritionists. With the creation of the new form 
for reporting ADRs for all healthcare professionals, they can submit their reports: until 
that time the Portuguese system only had forms for physicians, nurses and pharmacists 
and it was impossible for other professionals to report adverse reactions when they were 
dealing with them. The involvement of various groups of healthcare professionals has 
been progressive, which might represent a solution for increasing the rate of spontaneous 
reporting by health professionals. Although spontaneous reporting is a professional' duty, 
therefore, HCPs must report ADRs, there is underreporting in the Portuguese system, 
according to international guidelines. 
Since July 2012, with the implementation of the new Directive,(4) it is also possible to 
patients to report directly to SNF. However, the country’ ADR reporting figure of 295 per 
million population (2012) falls far short of the ideal rates of notification and even below 
from the WHO target (Fig. 1 and Fig. 2). 
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Physicians were represented 
since the beginning of the SNF. 
Pharmacists were incorporated 
into pharmacovigilance in 1995, 
and reported in collaboration 
with physicians, who validated 
their reports until 1997. 
From 1997 pharmacists were 
allowed to report directly to 
health authorities. 
Nurses are participating in the 
SNF since 2000, accounting for 
the majority of adverse reactions 
to vaccines. 
New report form – single format 
record for all HCP – it became 
possible for other classes of HCP 
to report, including PhT and 
nutritionists. 
With the implementation of the 
new Directive, it is also possible 
to patients to report directly to 
SNF. 
Major Educational Intervention in 
Practitioners and Pharmacists by 
UFN (from 2004 to 2008). 
Year | Number of reports 
Figure 1 - Spontaneous Reports received by SNF and the actions taken to their growth. 
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Spontaneous ADR reporting in Portugal is performed by all stakeholders to SNF, by filling 
online form or on paper (sent by mail, fax or email) or through phone.(35) The 
spontaneous reporting by healthcare professionals remains an effective resource for ADR 
detection; although, underreporting remains a reality, with consequent limitation in the 
risk evaluation and detection and delay risk signal generation. It is estimated that only 6% 
of all adverse reactions are reported.(19) 
In order to understand the reasons for underreporting in Portugal, it became necessary to 
identify the attitudes and knowledge of healthcare professionals associated with 
underreporting of ADR, based on reasons proposed by Inman.(37) 
Knowledge and attitudes of healthcare professionals are more related to spontaneous 
ADR reporting than the personal and professional factors, reinforcing that knowledge and 
attitudes are potentially modifiable, so that educational interventions designed based on 
the detected gaps in knowledge and attitudes of health professionals can improve 
favorably the report rates and quality.(7, 36, 38-40) 
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Figure 2 - ADR reports received in SNF from 1992 to 2013 (Adapted from: http://www.infarmed.pt) 
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In the future, a strengthening of the Pharmacovigilance System is needed, with further 
motivating healthcare professionals and patients to participate in the pharmacovigilance 
system and designing new strategies to promote ADR reporting, in order to minimize the 
risks with medicines and improve patient safety.(33) Regional Pharmacovigilance Units in 
Portugal should promote training and information in order to achieve the European 
report targets. The Harmonization of Pharmacovigilance, with the implementation and 
application of new European directives reveal themselves as tools to increase of patient 
safety. Also, the creation of European and global networks of pharmacovigilance, like 
European Medicines Agency Pharmacovigilance Risk Assessment Committee (PRAC) 
improves the easier and faster access to 
medicines information, assessing all 
aspects of the risk management of 
medicines for human use.(43) 
Patient reporting is available in Portugal 
since July 2012 and after the 
implementation of EU directive until 
December 2013, the National 
Pharmacovigilance System had received 
4987 spontaneous ADR reports, of which 
only 1,28% (n=64) were reported by 
patients.  
 
1.3. THE PATIENTS’ ROLE IN ACTIVE SURVEILLANCE  
Under-reporting of ADRs by healthcare professionals is a well-recognized problem 
worldwide. The patients’ role in actively reporting ADRs is a major factor to improve the 
global pharmacovigilance system: the pharmacovigilance impact of direct patient 
reporting could be one of the measures to reduce the rate of under-reporting by HCPs.(19) 
The importance of direct patient reporting has been highlighted by new European 
Table 1 - Number of patient reporting vs Total Amount of 
Reports, since new legislation application
(41, 42) 
 Reports by 
Patients 
(relative %) 
Total of Reports 
Received 
3
rd
 Trim. 2012 0,8% (n=6) 738 
4
th
 Trim. 2012 1,0% (n=8) 788 
1
st
 Trim. 2013 1,3% (n=12) 920 
2
nd
 Trim. 2013 1,0% (n=8) 789 
3
rd
 Trim.2013 1,3% (n=9) 720 
4
th
 Trim. 2013 2,0% (n=21) 1032 
Total 1,3% (n=64) 4987 
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legislation on pharmacovigilance, in order to strength spontaneous reporting systems in 
Europe.(24)  
The introduction of patient reporting in pharmacovigilance indicates a change in attitude 
in which patient reporting is valued due to their potential to contribute with useful 
information on drug safety, which can be used or maximized.(10, 31)  
However, there has also been some discussion about the role of patients in 
pharmacovigilance, mainly about the acceptance of ADRs reported by patients to 
spontaneous reporting systems: patient reporting could be particularly important to 
detect serious, unrecognized or unexpected ADR related to a new drug. In the scientific 
discussion about patient reporting, it could be considered both an opportunity and a 
threat for spontaneous reporting systems.(29, 44, 45)  
The lack of experience with patient reporting has been a contributing factor to this 
discussion. Over the years, and despite of the attempt to improve the quality and 
quantity of reports received, Pharmacovigilance has witnessed what some have called a 
patronising view on the reporting by patients.(46) This view was based on the idea that the 
suspected unwanted effects were sifted first by prescribers, who could decide whether 
the alleged problems were worth reporting, in order to reduce the amount of unwanted 
and useless data that was collected.(46) The under-reporting by healthcare professionals, 
the potential distortion of patient’ descriptions and the reluctance of patients to report to 
an healthcare professional were key factors to incorporate patients in spontaneous 
reporting systems. There is some evidence that patients report an ADR when they 
consider their health professional has not paid attention to their concerns.(29) 
Despite of patient spontaneous reporting increase the total amount of reports collected, 
it is essential to understand if the collected data are useful and that signals of important 
ADRs can be detected earlier than in the absence of patient reports.(45) 
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1.3.1.  Possible drawbacks of patient reporting 
Sceptics of patient reporting have argued that the data collected by patient reporting is 
usually unsystematic and incomplete.(45) Also, lack of awareness of the possibility to 
report and patients’ limited knowledge about their medications were viewed as main 
barriers to an effective patient reporting. In the debate surrounding the value of patient 
reporting, some major drawbacks of patient reporting are also mentioned– first the extra 
resources involved and secondly the potential for losing support from health 
professionals who may feel that their report is not needed.(29, 44, 45) Patients’ reports may 
contain incorrect clinical attributions of symptoms to specific medicines and the quality of 
reports might be lower than those made by healthcare professionals, and might have an 
higher proportion of non-serious or already known reactions.(29) Most Pharmacovigilance 
Centers do not seek medical confirmation for each patient report, and in most of the 
cases, HCPs are only contacted in very serious cases or when the organizations are 
looking into a potential new signal.(10) Major drawbacks could also include the possible 
duplication of the same ADR reports, and an increased number of reports, creating 
additional “noise” that could distract from signal detection, and result in system overload 
and additional administrative costs.(29) 
 
1.3.2. Possible benefits of patient reporting 
The contribution of direct patient reporting to pharmacovigilance has been explored in a 
number of studies.(27, 28) Since patient reporting has become more common, an increasing 
number of studies have shown that patient reporting has more potential benefits than 
drawbacks,(29, 44) indicating that new or different types of ADRs can be identified and 
described by patients themselves,(10) and contributing to a better knowledge of their 
impact on daily life.(27, 28, 47, 48) 
The information of patients is richer in their descriptions of behaviors and feelings than 
that from the health professional and often better explains the nature, meaning and 
consequences of ADRs. Patients reported that they usually initiated the discussion of the 
possible relationship between the drug and symptoms. Initial results obtained with the 
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direct reporting by patients demonstrate their ability to report adverse reactions for 
themselves or their immediate family, and show some differences with health 
professionals in the assessment of these adverse reactions and also the type of 
reactions.(26) 
Patient reporting experience from different countries seems to be favourable, and 
patients are well positioned to provide valuable post-marketing information on medicines 
and to report possible ADRs. Patients reporting has already led to important contributions 
in valuable information on drug safety.(31) Patients may contribute to the detection of 
known and unknown ADRs, symptoms or signs earlier than HCPs,(49, 50) and they may 
identify some different ADRs from those reported by HCPs or those which not feature in 
existing product information, contributing to a better knowledge of the nature and 
incidence of ADRs.  
Despite of additional noise that could be caused by the increasing of false ADR reports 
from patients, the experience with patient reporting in other countries, such as the UK, 
showed that more signals were detected when reports of suspected adverse reactions 
from both consumers and health professionals were collected.(31) 
Patients’ descriptions of suspected adverse reactions were more detailed than those of 
health professionals and were more likely to explain the effect of the reaction on the 
patients’ life.(28) Avery et al.(28) have shown the differences between patients and HCPs 
concerning to the type of drugs and events they report, and how signals of some drug-
related reactions might not emerge unless evidence from patients is integrated with that 
from professionals. 
Additionally, patients often supply more detail on how unwanted reactions actually affect 
their lives.(28, 46) The impact of ADRs on patients’ lives is not well understood. Apart from 
physiological effect of ADRs, patient reporting presents variable experiences of emotional 
impact: disbelief, anger, fear, frustration and isolation as common among patients that 
suffered an ADR.(51) 
The differences between reports by patients and by HCP indicate different points of view 
that can enrich spontaneous reporting. Adding patients to the range of potential 
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reporters of ADRs may increase spontaneous reporting and contribute to faster signal 
detection(26) and promote the perception of the impact that these ADR can have in 
people’s lives, that leads to better information collection on the adverse effects of drugs 
and also to give useful details about other problems with treatments, such as inadequate 
prescriptions or incorrect use of drugs, which would be very difficult to obtain 
otherwise.(26) 
The introduction and active participation of patients in the reporting schemes can make 
the public aware of possible ADRs and adds value to pharmacovigilance.(44) The access to 
leaflet information on adverse reactions(49) and HCP’ advices helps them to make 
informed choices about whether or not to use medicines and to recognize ADRs when are 
experiencing them.(44) The potential benefits of patient report include the promotion of 
consumer rights and equity, increasing the knowledge of consumers concerning 
medicines utilization and safety, and the opportunity to have unique perspectives and 
experiences; healthcare and patients organizations would also benefit from consumer 
involvement.(28, 44) The involvement of patients directly in Pharmacovigilance was 
regarded important to provide the patient perspective to manufacturers and regulators, 
but also because of dismissive attitudes and under-reporting by health professionals.(44) 
Patient self-reporting could refer subjective experiences, more sensitive to underlying 
changes in patients’ life,(49) that could be even more complete in behavioural aspects and 
subjective elements,(49) and show a better understanding of the effect of the ADR on the 
patient life, instead of healthcare professionals’ reports that usually consists of a 
description of symptoms and is more focused on clinical information.(44) Some studies 
shown that clinicians systematically downgrade the severity of patients’ symptoms, that 
patients’ self-reports frequently capture side effects that clinicians miss, and that 
clinicians’ failure to note these symptoms results in the occurrence of preventable 
adverse events.(49, 52) 
A recent study from The Netherlands has also explored patients’ motives and opinions 
about the reporting of suspected ADRs through qualitative interviews and a questionnaire 
sent to patient reporters.(47, 53) This study has characterized patient motivation to report 
an ADR, mainly in two major groups: altruistic and personal reasons. In altruistic motives, 
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the interests or welfare of others or the public interest was a reason for reporting. 
Altruistic motives concerned preventing harm to other patients, making the ADR publicly 
known, increasing medical knowledge, and wanting to improve the patient information 
leaflet. Personal motives for reporting an ADR included wanting more information about 
the ADR, indicating that the ADR was too severe not to report, being angry, or wanting 
confirmation about the ADR, or when they consider that an HCP has not paid attention to 
their concerns.(47, 53) Patients’ reasons to report ADRs include the severity of reaction and 
their impact on daily life.(48) The opportunity to share their experience in order to prevent 
harm to other people and contribute to research and knowledge(47) and the curiosity to 
find out if other people had experienced the same effect or symptom are also major 
reasons to report. Greater understanding of the reasons for reporting could be beneficial 
in marketing strategies aiming to increase the number and quality of reports. 
Comparisons of patients and healthcare professionals’ reports found that patients can 
provide a valuable contribution for signal detection and in some studies it has been 
shown that patients and healthcare professionals’ reports contribute in equal proportion 
to generate signals, and the combination of both, generated more potential signals than 
healthcare professionals’ reports alone. A review conducted in 2011 concluded that 
adverse event reports submitted by consumers can help significantly in early detection of 
safety signals.(28, 29) Although, healthcare professionals and patients have different views 
regarding ADR reporting, so, in order to assess the true nature of the ADR, it is important 
to receive reports from both groups.(48) Patients reported a higher percentage of known 
and non-serious reactions than HCP. Drugs widely used in the community setting, and 
over-the-counter (OTC) products, were the drugs most frequently reported by patients. In 
contrast, few reports involving reactions to antineoplastic agents or contrast media — 
drugs mostly used in a hospital setting — were sent by patients.(26) 
Contrary to earlier concerns, the quality of reports is generally good. Patient reporting of 
suspected ADRs has the potential to add value to pharmacovigilance by: reporting 
different types of drugs and reactions than those reported by HCPs; generating new 
potential signals; and describing suspected ADRs in enough detail to provide useful 
information on likely causality and impact on patients’ lives. These findings suggest that 
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further promotion of patient reporting schemes are justified, along with improvements to 
existing reporting systems.(28) If patient reporting is recognized as beneficial for 
pharmacovigilance and further optimized, methodology and best practice must be 
internationally shared and promoted. 
The awareness that patients can report ADRs is still thought to be low in most countries. 
However, patients’ reporting is not actively promoted in all countries, mainly because the 
organizations are lacking resources to organize large publicity campaigns and/or to 
handle a large number of reports in addition to healthcare professional’ reports. Also, in 
some countries, experiences with media attention about safety issues had increased 
reporting in a positive way, increasing awareness of the reporting scheme to the 
public.(10, 54) Greater publicity and promotion of the reporting scheme by healthcare 
professionals, plus wider availability and accessibility of the reporting forms were 
required.(10, 55) 
A better understanding of patient reasons and opinions regarding spontaneous reporting 
will improve the robustness and ability of pharmacovigilance system relating to the 
reduction of underreporting, covering blind spots of pharmacovigilance systems like 
herbal drugs or OTC medication and improve faster signal detection. 
High quality of information to patients is crucial, as good information on medicines and 
adverse drug reactions can empower patients to participate more actively in healthcare-
related decisions, together with health professionals.(22, 23, 29) 
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1.4. JUSTIFICATION OF STUDY AND OBJECTIVE 
Although some patients are aware they can report ADRs directly, more insight in patients’ 
attitudes and knowledge regarding ADR reporting should be gained in order to improve 
the quality and quantity of patient reporting, leading to a better and faster knowledge 
about drug safety. 
The objective of this survey is to describe the attitudes and knowledge of the patients 
regarding spontaneous reporting and the factors that can influence patients ADR 
underreporting in Portugal, in order to gain insight in why patients do not report more 
and how to possibly tackle this problem in Portugal.  
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2. METHODS 
A descriptive-correlational study was conducted looking for patient attitudes and 
knowledge regarding spontaneous reporting. Patients were asked about the reasons to 
report and opinions about reporting ADRs. The current study provides an adequate 
exploration about what motivates patients to report an ADR and the reasons and 
opinions about reporting. 
This chapter will describe the methodology used, which includes the search strategies for 
a literature review and data collection and the questionnaire design. This is followed by 
the definition of the study population, administration of the questionnaire by personal 
face-to-face interviews, statistical methodology and data analysis description. 
 
2.1. THE LITERATURE RESEARCH 
For the development of the scientific background that sustains this study, a literature 
search was conducted using  online databases – PubMed and Google Scholar – of 
published articles, using queries with specific keywords and MeSH terms combined with 
the Boolean operators; articles were selected based on a primary analysis of title and 
abstract. Keywords used included “patient reporting”, “pharmacovigilance”, “ADRs”, and 
“reporting systems”, including the articles in which “attitudes”, “knowledge”, “motives”, 
“opinions”, “reasons”, “benefits” and “drawbacks” concerning patient reporting were 
studied. Additional publications were found manually by identification on reference list of 
the extracted articles and in citation tracking. Thirty-four studies were selected by the 
interpretation of their titles and abstracts and the other 25 were added due to their 
scientific relevance.  
 
2.2. QUESTIONNAIRE DESIGN 
Based on information on patient reporting in the literature a survey was created in order 
to describe the attitudes and knowledge of the patients regarding spontaneous reporting 
and the factors that can influence patients ADR underreporting in Portugal. 
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The questionnaire was adapted from previous studies(44, 47, 55, 56) and translated to 
Portuguese by the author. The Portuguese questionnaire was field-tested by several 
volunteers, not eligible for the sample, in order to improve the translation and the 
understanding of the questionnaire. The final questionnaire includes two major sections: 
Section I asks about respondents’ characteristics (gender, age, education and working 
status) and the Section II relates to reporting attitudes and knowledge of the respondents 
about reporting. Some questions also asked about the possible suffered ADRs in the past 
and the attitudes regarding ADR-report knowledge. The whole questionnaire can be 
found in Appendix 1. Questions relating to reasons and opinions about reporting are 
shown in Table 2. 
Table 2 - Reasons and Opinions about reporting. Adapted from van Hunsel et al. (2010)
(47)
 
Reasons 
- R1- I wanted extra information 
- R2- The adverse drug reaction was severe 
- R3- It was difficult to discuss the adverse drug reaction with my medical practitioner or pharmacist 
- R4- The possibility for reporting an adverse drug reaction just exists 
- R5- I wanted to be heard 
- R6- Someone else pointed the possibility for reporting an adverse drug reaction 
- R7- I was angry about the situation 
- R8- I wanted action to be taken 
- R9 -I wanted to share my experiences 
- R10- The adverse drug reaction was not mentioned in the patient information leaflet 
- R11 -I was worried about my own situation 
Opinions 
- O1- Reporting an adverse drug reaction can prevent harm to other people 
- O2- I felt responsible for reporting an adverse drug reaction 
- O3- Reporting an adverse drug reaction that is already mentioned in the patient information 
leaflet is useless 
- O4- I only report an adverse drug reaction if it is serious 
- O5- Reporting an adverse drug reaction contributes to research and knowledge 
- O6- I report an adverse drug reaction if it is not mentioned in the patient information leaflet 
- O7- I benefit from reporting an adverse drug reaction 
- O8- Reporting an adverse drug reaction contributes to improvement of drugs 
- O9- I report an adverse drug reaction if it is unexpected 
- O10- In the future I will report a possible adverse drug reaction once again 
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The utilization of fixed statements to assess opinions and reasons about reporting, allows 
for the comparison between results and a greater reliability on response, once the 
questionnaire has been validated and previously applied.  
The reasons and opinions were rated at a five-point Likert scale (strongly agree to 
strongly disagree), where the middle position was labeled “neutral” to reflect a neutral 
position, and not an inability to answer the question. The main results were presented 
below in the Chapter 3. 
 
2.3. THE DATA COLLECTION 
Data were collected during 6 months (from June to November 2013). A large group of 
medicines’ consumers of a community pharmacy were selected as possible respondents 
and questionnaires were administered by personal interview. A convenience sample was 
used in order to collect data from medicines users. 
 
2.4. STUDY POPULATION 
The target population included the medicine consumers of a community pharmacy in 
Coimbra, Portugal. To give an impression of the size of pharmacy, there were 80743 
dispensations during the 6 months study period.  The main inclusion criteria included 
people who bought medicines or OTC medicines and that accepted to participate in the 
study. Another inclusion criteria was age: consumers under 18 years were not included. A 
record was made to avoid duplicate inclusions. The individual questionnaire was 
anonymous and the data were intended only for scientific purposes of this study and 
were stored in agreement with privacy regulations.  
 
2.5. DATA ANALYSIS 
The anonymized data were entered and subsequently analyzed using IBM® - Statistical 
Package for the Social Sciences (SPSS) software version 20.0 for Windows. 
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Descriptive statistics provided an overview of the patient characteristics, the reasons for 
reporting ADRs and the opinions of patients on reporting ADRs. 
A Pearson’s Chi-square (χ2) test was performed to detect significant differences in 
motives and opinions between patients of different age groups and levels of education 
and in differences in answers between men and women. Significance was based on a two-
sided χ2-test and significance was set at p<0.05. 
The Pearson’s Chi-square test (χ2) assumes a discrete distribution rather than a normal 
distribution, and Likert scale questions have a discrete range of answers, the results will 
be statistically valid and can be used as scientific proof. The expected counts were 
automatically printed in SPSS to check the assumption that the expected frequencies 
should be greater than 5. If the expected counts are less than 5, the results from the Chi-
square test are not statistically valid and Fisher’s exact test could be used.  
Since age categories and educational level can be seen as ordered categorical variables, 
we also calculated the χ² test for trend (depicted as the linear-by-linear association in the 
SPSS output). Significance was set at p<0.05 in the results we depict this by a Tvalue. 
Finally, correlations were carried out and interpreted to measure possible relationships 
between two or more statements. When data have been measured at only the ordinal 
level (like a Likert-scale) they are said to be non-parametric and Pearson’s correlation is 
not appropriate. Therefore, Spearman’s correlation coefficient was used in this analysis(57) 
and Bonferroni-adjusted significance level was calculated. A correlation coefficient of 0 
indicates no linear relationship, a coefficient of +1 indicates that the two variables are 
perfectly positively correlated, and a coefficient of -1 indicates a perfect negative 
relationship.(57) We considered a strong correlation if the correlation coefficient is greater 
than 0.7, a moderate correlation with a coefficient between 0.4 and 0.7, and a weak 
correlation if the coefficient is less than 0.4.  
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3. RESULTS 
General results are given by use of descriptive statistics. Answers to general questions 
and answers on the statements of reasons and opinions to report are shown in this 
chapter. 
 
3.1. RESPONSE RATE 
A total number of 1337 individuals were 
approached for a face-to-face interview. 
There were 1084 respondents, leading 
to a response rate of 81,1%. Of the 
responses, 2 questionnaires were not 
completed and were not taken into 
account. Among the 1082 
questionnaires totally completed 
responses, there were 134 responses 
(12,38%) by HCPs, that were also 
excluded for data analysis due to the 
bias created by these answers. The 
responses to the questionnaire are 
shown in Fig. 3 and the characteristics 
of the respondents are given in Table 3. 
The agreements to the statements are 
given in Table 8 and Table 9. The first 
gives the distribution of responses on 
the statements about reasons for 
reporting ADRs; the second shows the 
opinions about reporting ADRs.  
 
Figure 3- Flowchart of respondents to the questionnaire 
Table 3 - Respondent Characteristics 
Variable Percentage  
(Frequency) 
Gender 
   Male 
   Female 
 
40,8% (387) 
59,2% (561) 
Age 
   18-24 Years 
   25-34 Years 
   35-44 Years 
   45-54 Years 
   55-64 Years 
  65 + Years 
 
8,5% (81) 
18,4% (174) 
11,6% (110) 
23,3% (221) 
27,7% (263) 
10,4% (99) 
Educational Level 
   None 
   Basic Education (1st – 4th) 
   Elementary Education (5th -9th) 
   Secondary Education (10th – 12th) 
Universitary Formation 
 
1,1% (17) 
10,0% (95) 
33,5% (317) 
20,1% (191) 
34,6% (328) 
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3.2. GENERAL RESULTS 
Table 4 - Knowledge about the SNF and reporting in general 
 
  Do you know that is possible to reporting an ADR, 
either to SNF directly or through an HCP? 
D
o
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m
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 Yes No Total 
Yes 
506 
(53,4%) 
24 
(2,5%) 
530 
(55,9%) 
No 
316 
(33,3%) 
102 
(10,8%) 
418 
(44,1%) 
Total 
822 
(86,7%) 
126 
(13,3%) 
948 
(100%) 
 
Regarding attitudes and knowledge, 44,1% of patients never heard about SNF and 13,3% 
never heard about the possibility of reporting/sharing experiences of an ADR with an HCP 
or directly to the SNF. 53,4% knew about the SNF and the possibility to report an ADR. 
Younger people and those with a higher education were significantly more likely to be 
aware of SNF or the possibility of reporting/sharing an ADR: 
 
 Younger people were significantly more likely to be aware of SNF (χ
2 
p= .002 Tvalue: .004). There is 
also a difference in people from different age categories that know about the possibility of report (χ
2 
p 
= .015), however there was no trend when looking at the categories (Tvalue: .099). The classes 35-44 
years and 45-54 years know more about the possibility of report. 
 People with higher educational level were significantly more likely to be aware of SNF (χ
2 
p = <.001 
Tvalue: <.001) and to know about the possibility of report (χ
2 
p = <.001; Tvalue: <.001). 
 
Answers to other general questions regarding ADR reporting knowledge, attitudes and 
perception are shown in table 5: 
Table 5 - Participant responses on survey assessing knowledge of consumer ADR reporting systems 
 
Survey question % (respondents)* 
How did you learn about the possibility of reporting possible ADRs from 
medicines? † (n=822) 
    From a GP (General Practitioner) 61,2% (n=503) 
    From a Pharmacy 41,7% (n=343) 
    INFARMED Website 14,8% (n=122) 
    From a Hospital 10,7% (n=88) 
    Internet Research 6,1% (n=50) 
    Family member or friend 2,2% (n=18) 
    Magazine or Newspaper 1,5% (n=12) 
    School/Workshop 0,4% (n=3) 
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What’s for you the best way to do a report? (n=822) 
    Indirectly – through an HCP  62,4% (n=513) 
    Directly - Online / By Computer 31,6% (n=260) 
    Directly - by telephone  4,4% (n=36) 
    Directly - by post  1,6% (n=13) 
  
  
When you have/if will have a suspected ADR what do you do? †  (n=948) 
    Talk to your GP/Doctor 35,9% (n=340) 
    Talk to your Pharmacy 33,7% (n=319) 
    Make a spontaneous report 32,2% (n=305) 
    Stop the medication 17,1%( n=162) 
    Don't do nothing 5,3% (n=50) 
  
  
Have you ever had side effects from any medicine? (n=948) 
    Yes 57,6%  (n=546) 
    No 42,4%  (n=402) 
  
*Denominators vary due to missing responses and conditional questions. Cells do not always total 100% due to 
rounding. † Multiple answers allowed. 
 
Of the respondents, 57,6% had the perception that they had already suffered an ADR; 
although, only one patient had previously reported an ADR directly to SNF. Another two 
had reported through an HCP.  
All patients that already experienced an ADR but that didn´t report it, were questioned 
about reasons for non-reporting, see the following table: 
 
Table 6 - Reasons for not reporting the experienced side effect 
  
Reasons for not reporting the experienced side effect   (n=543) 
Side effect not serious enough  26,7%(n=145), 
Expected/knew side effect 19,5%(n=106) 
Didn´t realize side effect due to medicine 17,1% (n=93) 
Is unnecessary  12,2% (n=66) 
Stopped using medicine 10,9% (n=59) 
Other (including embarrassed, abroad, didn´t read instructions) 7,0% (n=38) 
Don’t know how to report 6,6% (n=36) 
  
 
On the other hand, patient that never perceived an ADR, received a question about the 
attitudes for the future: only 49,8% of the respondents that never had side effects from 
any medicine stated that in the future they would report if they had any side effect, see 
table 7. 
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Table 7 - Motivation to reporting in the future, if an ADR occurs 
  
In the future, if you have any side effects will you report?  (n=402) 
    Yes 49,8%  (n=200) 
    No 24,4% (n=98) 
    Don’t know/ Not Sure 25,9% (n=104) 
  
 
In order to understand the reasons and opinions about spontaneous reporting, all 
patients were asked about these. The following tables show the compliance with the 
statements: 
Table 8 - Motives for reporting adverse drug reactions (percentage (frequency)) 
Reasons Strongly 
Agree 
Agree Neutral Disagree 
Strongly 
Disagree 
I wanted extra information 23,63% 
(224) 
28,38% 
(269) 
27,85% 
(264) 
15,30% 
(145) 
4,85% 
(46) 
The adverse drug reaction was severe 55,06% 
(522) 
26,05% 
(247) 
12,03% 
(114) 
5,38% 
(51) 
1,48% 
(14) 
It was difficult to discuss the adverse drug reaction 
with my medical practitioner or pharmacist 
37,45% 
(355) 
25,42% 
(241) 
22,05% 
(209) 
11,50% 
(109) 
3,59% 
(34) 
The possibility for reporting an adverse drug reaction 
just exists 
24,79% 
(235) 
32,07% 
(304) 
29,85% 
(283) 
8,44% 
(80) 
4,85% 
(46) 
I wanted to be heard 36,60% 
(347) 
27,00% 
(256) 
22,36% 
(212) 
8,97% 
(85) 
5,06% 
(48) 
Someone else pointed the possibility for reporting an 
adverse drug reaction 
22,57% 
(214) 
16,98% 
(161) 
29,22% 
(277) 
22,89% 
(217) 
8,33% 
(79) 
I was angry about the situation 31,43% 
(298) 
30,06% 
(285) 
21,52% 
(204) 
12,03% 
(114) 
4,96% 
(47) 
I wanted action to be taken 28,48% 
(270) 
29,64% 
(281) 
21,52% 
(204) 
13,29% 
(126) 
7,07% 
(67) 
I wanted to share my experiences 19,51% 
(185) 
35,13% 
(333) 
22,36% 
(212) 
18,67% 
(177) 
4,32% 
(41) 
The adverse drug reaction was not mentioned in the 
patient information leaflet 
16,46% 
(156) 
17,09% 
(162) 
28,90% 
(274) 
29,01% 
(275) 
8,54% 
(81) 
I was worried about my own situation 46,73% 
(443) 
26,69% 
(253) 
16,98% 
(161) 
5,49% 
(52) 
4,11% 
(39) 
Cells do not always total 100% due to rounding 
The main reasons for patients to do a spontaneous report would be the severity of the 
reaction and worries about their own situation. Regarding opinions, patients believe that 
reporting an ADR can prevent harm to other people and that reporting contributes to 
research and knowledge or drug improvement. Patients also consider that it was difficult 
to discuss the ADR with HCPs, such as general practitioners or pharmacists. 
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Table 9 - Opinions about reporting adverse drug reactions (percentage (frequency)) 
Opinions Strongly 
Agree 
Agree Neutral Disagree 
Strongly 
Disagree 
Reporting an adverse drug reaction can prevent harm 
to other people 
53,59% 
(508) 
34,60% 
(328) 
6,54% 
(62) 
3,90% 
(37) 
1,37% 
(13) 
I felt responsible for reporting an adverse drug 
reaction 
12,87% 
(122) 
14,98% 
(142) 
25,21% 
(239) 
33,97% 
(322) 
12,97% 
(123) 
Reporting an ADR that is already mentioned in the 
patient information leaflet is useless 
38,29% 
(363) 
21,94% 
(208) 
19,20% 
(182) 
15,30% 
(145) 
5,27% 
(50) 
I only report an adverse drug reaction if it is serious 44,62% 
(423) 
22,26% 
(211) 
14,24% 
(135) 
13,71% 
(130) 
5,17% 
(49) 
Reporting an adverse drug reaction contributes to 
research and knowledge 
52,43% 
(497) 
27,32% 
(259) 
13,61% 
(129) 
6,12% 
(58) 
0,53% 
(5) 
I report an adverse drug reaction if it is not mentioned 
in the patient information leaflet 
43,14% 
(409) 
33,02% 
(313) 
14,24% 
(135) 
6,43% 
(61) 
3,16% 
(30) 
I benefit from reporting an adverse drug reaction 30,27% 
(287) 
20,78% 
(197) 
22,36% 
(212) 
20,04% 
(190) 
6,54% 
(62) 
Reporting an adverse drug reaction contributes to 
improvement of drugs 
49,05% 
(465) 
33,86% 
(321) 
9,60% 
(91) 
6,86% 
(65) 
0,63% 
(6) 
I report an adverse drug reaction if it is unexpected 19,73% 
(187) 
35,34% 
(335) 
23,31% 
(221) 
19,73% 
(187) 
1,90% 
(18) 
In the future I will report a possible ADR 13,19% 
(125) 
25,63% 
(243) 
33,12% 
(314) 
21,31% 
(202) 
6,75% 
(64) 
Cells do not always total 100% due to rounding 
 
3.3. DIFFERENCES IN RESPONSES BASED ON PATIENT CHARACTERISTICS  
 
Patients’ characteristics, knowledge regarding SNF and the opportunity to report ADR 
were compared with the other answers. Based on Pearson’s chi-square statistics, 
significant results are given, indicating that the answers were related to patient 
characteristics.  
 
Based on Gender: 
 Women show more agreement with “It was difficult to discuss the adverse drug reaction 
with my medical practitioner or pharmacist” (reason 3, χ2 p = .049). 
 Women show more agreement with “I was angry about my situation” (reason 7, χ2 p = 
.044). 
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Based on Age: 
 Younger people were significantly more likely to be aware of SNF (χ2 p= .002 Tvalue: .004). 
There is also a difference in people from different age categories that know about the 
possibility of report (χ2 p = .015), however there was no trend when looking at the 
categories (Tvalue: .099). The classes 35-44 years and 45-54 years know more about the 
possibility of report. 
 
 Older people show more agreement with “It was difficult to discuss the adverse drug 
reaction with my medical practitioner or pharmacist” (reason 3, χ2 p = <.001 Tvalue: 
<.001). 
 Older people show more agreement with “The possibility for reporting an adverse drug 
reaction just exists” (reason 4, χ2 p =.026 Tvalue: .019). 
 Older people show more agreement with “I wanted to be heard” (reason 5, χ2 p =.006 
Tvalue: <.001). 
 Older people show more agreement with “I was angry about my situation” (reason 7, χ2 p 
= .044 Tvalue: .003). 
 Older people show more agreement with “I wanted action to be taken” (reason 8, χ2 p = 
<.001 Tvalue: .007). 
 Younger people show more agreement with “The adverse drug reaction was not 
mentioned in the patient information leaflet” (reason 10, χ2 p = <.001), however there 
was no trend when looking at the categories ( Tvalue: .752). 
 Older people show more agreement with “I was worried about my own situation” (reason 
11, χ2 p = .002 Tvalue: <.001). 
 
 There is a difference between the age categories for agreement with the statement “In 
the future I will report a possible adverse drug reaction” (opinion 10, χ2 p = .028), however 
there was no trend for age ( Tvalue: .123). 
 
Based on Educational Level: 
 People with  higher level of education were significantly more likely to be aware of SNF ( 
χ2  p =  <.001 Tvalue: <.001 )    and  to  know  about  the  possibility  of  report (χ2 p = <.001 
Tvalue: <.001). 
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 There was a difference based on level of education for agreement with “I was worried 
about my own situation” (reason 11, χ2 p = .001). However there was no trend for this 
statement based on the level of education (Tvalue: .773). 
 
 People with higher level of education show more agreement with “I benefit from 
reporting an adverse drug reaction” (opinion 7, χ2 p = .010 Tvalue: <.001). 
 People with higher level of education show more agreement with “I report an adverse 
drug reaction if it is unexpected” (opinion 9, χ2 p = <.001 Tvalue: <.001). 
 People with higher level of education show more agreement with “In the future I will 
report a possible adverse drug reaction” (opinion 10, χ2 p = .026 Tvalue*: .045). b 
 
 
 
3.4. CORRELATIONS 
 
Spearman’s correlation coefficients between the statements were displayed in SPSS. All 
correlations between reasons and opinions, but also separately among the reasons and 
among the opinions, are presented in Appendix 3. 
The highest correlation coefficient found in the present data was 0.54. This means that a 
strong correlation between all statements was not present, only moderate and weak 
correlations were found. Therefore, it was difficult to define the meaning of the possible 
relationships between the statements. Nevertheless, moderate correlations are 
presented in Table 10 and Table 11 as indication of the results. 
 
Table 10 - Correlations Coefficients – reasons for reporting ADR 
Related Reasons Spearman rho** 
"Discuss ADR with HCP" (R3) and "Wanted to be heard" (R5) 0,51 
"Discuss ADR with HCP" (R3) and "Angry about situation" (R7) 0,43 
"Discuss ADR with HCP" (R3) and "Worried about situation" (R11) 0,39 
"Wanted to be heard" (R5) and "Angry about situation" (R7) 0,46 
"Angry about situation" (R7) and "Wanted action to be taken" (R8) 0,50 
"Wanted action to be taken" (R8) and  "Worried about situation" (R11) 0,52 
**correlation is significant at the .01 level (2-tailed)  
                                                          
* Marked variables were recoded in order to perceive the trend for age and educational level 
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The highest correlation was found between reason 8 “I want action to be taken” and 
reason 11 “I was worried about my own situation”. The correlation coefficient between 
the two reasons is .52 and the significance value of this coefficient is less than .01.  
 
Table 11 - Correlations Coefficients – opinions about reporting ADR 
Related Opinions Spearman rho** 
"Can prevent harm to other people"(O1) / "Contributes to research and knowledge"(O5) 0,40 
"Can prevent harm to other people" (O1) / "Contributes to improvement of drugs" (O8) 0,42 
"I will report in the future" (O10) and "I felt responsible for reporting" (O2) 0,47 
"Report ADR present in leaflet is useless" (O3) and "Only report if it is serious" (O4) 0,54 
“Contribute to research and knowledge"(O5) / "Contribute to improvement of drugs"(O8) 0,51 
**correlation is significant at the .01 level (2-tailed)  
 
The correlation coefficients between the opinions for reporting ADRs were also only 
moderate or even weak. No strong correlations were found. The highest correlation was 
found between opinion 5 “Reporting an ADR contributes to research and knowledge” and 
opinion 8 “Reporting an ADR contributes to improvement of drugs”. The correlation 
coefficient between the two opinions is .51 and the significance value of this coefficient is 
less than .01. 
Furthermore, correlations between both sections of the questionnaire, the reasons and 
opinions, were also carried out. However, this resulted in just one moderate correlation 
between reason 9 and opinion 2 (correlation coefficient = .42) and furthermore only weak 
correlations – Appendix 3.  
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4. DISCUSSION 
This section starts with a discussion of the status of Pharmacovigilance in Portugal, and 
the role of educational interventions in active Pharmacovigilance. The major findings and 
the relation to other studies with respect to the results are described in the Chapter 4.3 
and the Strengths and Weakness of the study are discussed in Chapter 4.4.  
4.1. THE STATUS OF PHARMACOVIGILANCE IN PORTUGAL 
In Portugal, the SNF is mostly based on a spontaneous ADR reporting method, being an 
effective resource for early detection of rare or unexpected ADR. The major limitation 
regarding the effectiveness of spontaneous ADR reporting system is underreporting of 
suspected ADRs, with consequent limitations in assessing the risk of drug and delay 
generation of risk signals, causing serious health repercussions. The identification of 
attitudes and knowledge of health professionals associated with underreporting in 
Portugal has become essential to understand the reasons for the underreporting of 
ADR.(7, 35, 36, 58) 
The number of ADR reports received by SNF from different classes of health professionals 
(pharmacists, physicians and nurses), as well as the pharmaceutical industry, has been 
increasing considerably (Fig. 1). Although underreporting remains a reality in 
pharmacovigilance and it’s estimated that only 6% of all adverse reactions are 
reported.(19) 
In the last couple of years, pharmacists were the HCPs who reported more than other 
HCPs to SNF, but whose participation in pharmacovigilance systems is quite variable,(35) 
depending of area of activity and country: in Portugal it is estimated that about up to 20% 
of spontaneous reports come from pharmacists, and their participation are variable 
between hospital and community  pharmacists.(7, 33, 36, 41, 42) However, the number of 
reports received from community pharmacists is growing, and they assumed a 
fundamental role in the monitoring of ADR events, since they establish the connection 
with the patient before, during and after treatment.(35) The active and important role 
Mestrado em Farmácia – Especialização em Farmacoterapia Aplicada 
  
  
32 
 
played by pharmacists in promoting reporting by patients and the good patient-
pharmacist relationship should be developed in order to promote active 
pharmacovigilance by patients, acting as facilitators and promoting patient’ ADR 
reporting.(26, 59) 
Many factors are associated with ADR underreporting among health professionals and 
these have been broadly classified. Inman(40, 60) has summarized these factors as the 
“seven deadly sins”. His description of the “sins” include: attitudes relating to professional 
activities (financial incentives: rewards for reporting; legal aspects: fear of litigation or 
enquiry into prescribing costs; and ambition to compile or publish a personal case series) 
and problems associated with ADR-related knowledge and attitudes (complacency: the 
belief that very serious ADRs are well documented by the time a drug is marketed; 
diffidence: the belief that reporting an ADR would only be done if there was certainty that 
it was related to the use of a particular drug; indifference: the belief that the single case 
an individual doctor might observe could not contribute to medical knowledge; and 
ignorance: the believe that it is only necessary to report serious or unexpected ADRs), and 
excuses made by professionals (lethargy: the procrastination and disinterestedness in 
reporting or lack of time to find a report card and other excuses).(60) 
Lopez-Gonzalez et al.(40) have shown that three of the seven “sins” proposed by Inman 
that are associated with professional activity (financial incentives, fear and ambition to 
publish) seem to contribute less significantly to underreporting. Insecurity (the belief that 
it is nearly impossible to determine whether or not a medicine is responsible for a 
particular ADR) is another factor associated with underreporting(40) but was not proposed 
by Inman. 
Those findings suggests that health professionals need to be informed about ADRs and 
perhaps to change their practice.(44) In order to improve the reporting rate, it is important 
to improve the knowledge, attitudes and practices of the HCPs (and patients) regarding 
ADR reporting and Pharmacovigilance. Two case-control studies were carried out for 
physicians and pharmacists, whose results allowed, for the design of educational 
interventions in order to increase the rate of spontaneous reporting.(7, 36, 58, 61) Educational 
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interventions increased the number of spontaneous reports received in SNF, leading to a 
peak of spontaneous reports in 2004 by practitioners and pharmacists, reflecting the 
result of the educational intervention developed at UFN, as shown in Fig. 1. 
Subsequently, reinforcing interventions have been conducted in order to improve 
reporting.(36, 61) The knowledge and attitudes of health professionals are more related to 
spontaneous ADR reporting than personal and professional factors, reinforcing the 
premise that knowledge and attitudes are potentially modifiable, so that educational 
interventions designed based on the detected gaps in knowledge and attitudes of health 
professionals can favorably improve reporting.(36, 38-40, 61) 
 
4.2. ADVANTAGES AND DISADVANTAGES OF APPLICATION OF EDUCATIONAL 
INTERVENTIONS FOR PATIENTS 
Educational interventions made for HCPs have significantly increased the number and 
relevance of spontaneous ADR reports in Portugal. This increase declines over time(61) and 
therefore, regular training should be repeated periodically to keep the participation of 
HCPs in Pharmacovigilance. These should include discussion of the attitudes of HCPs 
regarding spontaneous ADR reporting, with attention for the main reasons for 
underreporting.(38) 
Likewise, potential educational interventions targeting patients could be developed, 
focusing the attitudes associated with underreporting of ADR by patients identified in this 
study and the dissemination of information by patients. Patients’ associations should be a 
primary target, for being more aware to medicines safety issues. The administrative and 
financial capacity of the SNF should be taken into account when educational interventions 
are prepared because structural intervention could be needed to facing the increase of 
reports received: a spontaneous reporting “boom” may be inappropriate in terms of costs 
and human resources. According to Hexheimer et al.(62) the pharmacovigilance systems 
must be restructured to enable direct patient reports to be appropriately handled, that 
require more pharmacovigilance staff, with new training to learn to analyze qualitative 
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data and time. The increase in quantity of the number of reports received should also be 
reflected in an increased quality and faster detection signal. 
A wide range of educational interventions, such as the broadcast of television programs 
on some medicines(54) have also reported an increased patient reporting which 
demonstrates the vital role that patients can have in Pharmacovigilance systems if they 
are made aware that they can report.  
 
4.3. MAIN FINDINGS 
The main objective of this survey was studying the attitudes and knowledge of the 
patients regarding spontaneous reporting and the factors that can influence patients ADR 
underreporting in Portugal. 
The questionnaire resulted in a high response rate of 81,1%, but about 12% of 
respondents were HCP who were excluded from data analysis due to the possible bias 
created by their knowledge regarding study issues.  The high number of HCP interviewed 
could be related to the existence of a huge healthcare pole in Coimbra, that is one of the 
biggest employer of central region of Portugal. Regarding this, the high percentage of 
respondents that knows about the SNF and the possibility to report an ADR could be 
related to the proximity to healthcare pole and the existence of patients-HCP proximity 
that create more knowledge regarding health issues, due to social relation. 
55,9% of respondents knows about SNF and 86,7% knows that it is possible to report an 
ADR, either to SNF directly or through an HCP; these possibilities were learned mainly 
from practitioners and/or pharmacy. Despite of this good result, for 62,4% of the 
respondents, the best way to report is indirectly through an HCP, which we could relate 
to indifference, ignorance of report directly and insecurity to determine causal 
relationship between the drug and the reaction, already described by Inman as reasons 
for underreporting.(60)  
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Despite all efforts to potentiate the online reporting, only 31.6% of respondents prefer 
this method above other methods. This result is consistent with the SNF results, online 
reporting is still little used in Portugal.(42) 
Asked for what they do when they have or if will have an ADR, patients answered that 
they talk to their GP (35,9%) or to their pharmacy (33,7%). Although, as discussed above, 
communication with HCP is a major barrier indicated by patients to do a spontaneous 
report. Making a spontaneous report was also pointed by 32,2% of respondents as an 
action to do when they have an ADR, but only 3 of the respondents had already made a 
spontaneous report. Coimbra, where this study was performed, is located in Central 
Portugal which is the geographic region that receives less ADR reports.(41, 42) Social 
desirability bias could be an issue with the question about making a report.  
As shown by Inman, there are several reasons related to knowledge and attitudes that 
could be related to underreporting. The reasons found by HCP could easily be 
demonstrated as the same by patients. Complacency (“side effect not serious enough”) 
diffidence (“it’s unnecessary”), ignorance and indifference (“expected/knew side effect”) 
and insecurity (“didn’t realize that side effect is due to the medicine”) are pointed as the 
main reasons for not reporting the experienced side effects.(60) 
It appeared that patients are motivated to report ADR due to several reasons. The most 
important motives are the severity of the reaction (81,1% agree or strongly agree) and 
they were worried about their situation  (73,4% agree or strongly agree). The need to be 
heard (63,6% agree or strongly agree) and difficult to discuss the ADR with medical 
practitioner or pharmacist (62,9% agree or strongly agree) were also main  factors to do 
spontaneous report directly by patients. 
The need to be heard and the difficulty to discuss the ADR with HCP suggest that 
communication between patient and HCP should be improved. It can also reflect the 
insecurity regarding identification of ADR and the acknowledgement of HCP to handle 
with ADR proposed by Inman as a motive of underreporting.(60) 
Furthermore, patients believe that reporting an ADR can prevent harm to other people 
(88,2% agree or strongly agree), that reporting contributes for improvement of the drugs 
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(82,9% agree or strongly agree) and to research and knowledge (79,8% agree or strongly 
agree). 
Portuguese patients also pointed out being angry about their situation as a main motive 
to report an ADR. It could reflect that ADR knowledge should be improved among 
patients and the ADR should be clarified to the patients, in order that they understand 
that is an inherent possibility of the medicines use.  
After subdividing the answers on the statements based on the patient characteristics, it 
appeared that gender, age and level of education had a significant effect on the reasons 
to report an ADR and/or the opinions about reporting ADRs and also for the knowledge 
about the possibility of report an ADR and/or about the existence of SNF. More 
information is needed for patients, especially for older and with lower educational level 
that demonstrates lowest level of literacy in relation to pharmacovigilance and ADR 
reporting. 
Only moderate and weak correlation coefficients between the statements were found. 
For the most significantly related reasons and opinions an explanation can be thought of. 
The difficulty to discuss the ADR with an HCP (reason 3), the need to be heard (reason 5) 
and being angry about situation (reason 7) are related aspects. The worries about their 
ADR (reason 11) and wanting action to be taken (reason 8) also show a relation with 
these reasons. 
With concern to opinions on reporting, for respondents, a relation is found between 
reporting ADR contributes to research and knowledge (opinion 5) and for improvement of 
the drugs (opinion 8), which seems reasonable. In turn, a better future situation can 
prevent harm to other people (opinion 1), the feel of responsibility of reporting an ADR 
(opinion 10) and the intention for reporting in the future (opinion 2) are also related, 
which indicated that potential modifications in empowering patients with regard to these 
questions can lead to increased reporting in the future. 
On the other side, the strongest correlation of the study is between “reporting an ADR 
present in the patient information leaflet is useless” (opinion 3) and “ I only report if the 
ADR is serious” (opinion 4)  are also statements with a high agreement. These attitudes 
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were already described by HCP,(60) and should be priority issues for educational 
interventions on patients. 
4.4. COMPARISON WITH OTHER STUDIES 
Several studies have been conducted with the aim of investigating motivations of 
healthcare professionals for reporting ADRs.(7, 20, 21, 38-40, 58, 63-65) The severity of the 
reaction was the main factor determining the ADR report or not.(65) Hasford et al.(64) and 
Ekman et al.(63) indicated that the severity of the reaction, unusual reactions and 
reactions caused by a new drug were the main reasons motivating HCP to report ADRs. 
The desire to contribute to medical knowledge, reaction previously unknown to the 
reporter, reaction to new drug, desire to report all significant reactions, known 
association between drug and reaction and severity of reaction are also motives that 
incentive HCP to report an ADR.(66) 
Some of the motives found for HCPs are also important reasons for patients to report, 
such as severity of the reaction and wanting to contribute to medical knowledge. 
According to a similar study conducted in The Netherlands in patients that already sent a 
spontaneous reporting to Netherlands Pharmacovigilance Centre- Lareb by van Hunsel et 
al.(47), “the severity of the adverse reaction” and the “need to sharing experiences” were 
the main reasons to patient reporting.  
Among the altruistic motives, preventing harm to other patients, making the ADR publicly 
known, increasing medical knowledge and wanting to improve the patient information 
leaflet were indicated as reasons to report. Personal motives to report an ADR included 
wanting more information about the ADR, indicating that the ADR was too severe not to 
report, being angry or wanting confirmation of their ADR.(47) 
Other studies also expressed altruistic views indicating the need to make the ADR public 
or making other patients aware of side effects from medicines and also to prevent others 
from suffering similar problems.(44) The importance of highlighting the patients’ 
perspective on suspected ADRs, particularly their severity and impact, was also described 
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by Anderson et al.(44); unexpected reactions to a widely used medicine and worse side 
effects than the underlying medical problem were also motives among reporters in UK. 
Respondents also indicated that the severity of symptoms may be perceived differently 
by patients and that patient reports might differ from those of HCP.(44) 
Despite of our study being conducted similarly to previous studies, the differences in 
responses between reporters and non-reporters are evident. It can be easily understood 
thatthese differences in results are based on the fact that our respondents never made a 
spontaneous reporting before and are due to lower knowledge shown regarding 
Pharmacovigilance. Respondents did not show so much altruistic motives which concerns 
to patient attitudes and knowledge on reporting. 
Among the altruistic motives present in the motives and opinions of report, all of them 
show less agreement than in the similar study performed in The Netherlands.(47) The 
greatest differences are present in the “wanting to share experiences” - only 54,6% of the 
respondents shows agreement with this statement, instead of 89,0% in the compared 
study;(47) likewise, patients didn’t “feel responsible for reporting an adverse drug 
reaction” - only 27,9% of the respondents shows agreement with this statement, instead 
of 90,7% in The Netherlands;(47) “reporting an adverse drug reaction can prevent harm to 
other people”, “Reporting contributes to research and knowledge” and “ Reporting can 
help the  improvement of drugs” shown similar results.  
Comparing the knowledge about the ADR reporting, our results are consistent to earlier 
studies(44, 55) regarding to how respondents learned about the possibility of reporting 
possible ADRs, which shows that most of patients learned it from their pharmacy or GP. 
Comparing the attitudes concerning the type of reactions to be reported there are also 
some interesting findings. Patients states that “reporting an ADR present in the patient 
information leaflet is useless” (60,2%) and “I only report if the ADR is serious” (66,9%): 
this ignorance about the types of reactions that should be reported should be addressed 
by providing useful information to patients; on the other side, “the ADR was not 
mentioned in the leaflet”(33,6%) and “reporting an ADR if it is unexpected”(50,1%) 
doesn’t pointed as major reasons to report, that could represent insecurity from patients 
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to establish causal relation, or even complacency that medicines are safe and ADR are 
well documented by the time the drug is marketed. 
The HCP-patient communication barrier has also been discussed in other studies: the 
issue of dismissive attitudes among HCPs and their failure to report ADRs was already 
discussed(44) and some patients were concerned that GP reports may not always be 
accurate and that doctors may not even consider suspected ADRs, expressing a lack of 
awareness among health professionals about patient reporting and the need for  
reporting mechanism independent of health professionals and for patients’ voices to be 
heard.(44) 
A final statement intended to understand the action of patients if they experience a 
possible ADR in the future, shows an evident difference with the previously performed 
study in The Netherlands. Only 38,8% of Portuguese patients appear to be motivated to 
do a report of ADR in future. About one third are not sure about what to do and 28,1% 
even say that would not report. This could be explained by the fact of our respondents 
never reported an ADR before, contrary to the patients of The Netherlands study. 
 
4.5. STRENGTHS AND WEAKNESSES OF THE STUDY 
4.5.1. Strengths 
 The questionnaire has been partly validated previously in another study. The 
utilization of a developed instrument for gaining insight in patient-motives for 
reporting ADRs it’s a measure to improve the robustness of data collected. 
 High response rate: the high response rate could be considered one of the 
strengths of the study. We attempted to explain high response rate achieved 
below in the chapter 5.3 – Bias. 
 As far as we know, this is the first national study regarding patients reporting. 
Further opportunity for a purposive sample of reporters to describe their opinions 
should be taken. However, patients that had reported to the SNF constitute a 
minority of the population. 
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4.5.2. Weaknesses  
 Proper randomization was not possible in selecting patients, mainly due to the 
selection method of sampling (convenience sample). 
 Comparison of data collected with other studies carried on patients that already 
report ADR, could reflect inconclusive and non-comparable results. 
 There are some differences between our study population (Table 12) and the 
general Portuguese population, which suggests that our results cannot be 
extrapolated fully to the Portuguese population. 
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5. VALIDITY 
This Chapter discusses validity aspects of the study, like the study population and 
respondent characteristics. 
5.1. SELECTED POPULATION STUDY 
The sample of patients was limited to one Portuguese region, from an urban area, which 
could create a bias in final results. For this preliminary study in a Portuguese population 
face-to-face interviews were chosen in order to do not discard the older or lower-literacy 
population so that they would be represented in the study. Despite of this, bias could also 
be related to the population of the study that lives in Coimbra. The city is better known 
for its university, the great quantity of students and when it was created a reference pole 
of health services in Portugal (with the University Hospitals that are a huge health pole of 
Portugal), which could create positive bias concerning educational level and more 
knowledge regarding health issues, which are both higher than expected for Portuguese 
population. It is estimated that the high response rate and the huge amount of 
respondents knowing about SNF could be related with it. 
 
5.2. RESPONDENTS’ CHARACTERISTICS 
In the comparison of patient characteristics of study population to the Portuguese 
population we could find similarities and differences in characteristics. The comparison 
between study sample and Portuguese population is represented in the table 12. 
Analysing the variables under study, it appears that gender does not appear to have 
differences that may have interference in the results. However, regarding to age, the 
comparison with the general Portuguese population shows us that there is a greater 
representation of [45-64] classes, which results in an underrepresentation of the elderly 
class of 65+ years. 
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With concern to education, the discrepancies are even more evident. There is an 
underrepresentation of classes with lower-literacy, resulting in an overrepresentation of 
tertiary education classes. Although, we thought that the results reflect the trend of the 
general population concerning to attitudes and knowledge regarding ADR report, 
however, caution is needed before extrapolating these data to the general population, 
because older(67) or lower-literacy populations cannot be represented correctly, and even 
worst results are expected in rural areas, with lower-literacy and older populations. 
 
 
 
 
Table 12 - Respondent Characteristics vs. Characteristics of Portuguese Population 
Variable Sample 
Percentage  
Portuguese 
Characteristics 
Gender 
   Male 
   Female 
 
40,8% 
59,2% 
 
46,9% 
53,1% 
Age 
   18-24 Years 
   25-34 Years 
   35-44 Years 
   45-54 Years 
   55-64 Years 
  65 + Years 
 
8,5% 
18,4% 
11,6% 
23,3% 
27,7% 
10,4% 
 
9,2% 
15,4% 
18,7% 
17,6% 
15,4% 
23,6% 
Educational Level* 
Pre-primary, primary and lower 
secondary education (levels 0-2) 
Upper secondary and post-secondary 
non-tertiary education (levels 3 and 4) 
First and second stage of tertiary 
education (levels 5 and 6) 
 
 
45,3% 
 
20,1% 
 
34,6% 
 
 
63,4% 
 
20,3% 
 
16,3% 
Source: EUROSTAT 
*Educational level was reclassified according to ISCED and levels are grouped to easier comparison. 
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5.3. TYPES OF BIAS 
5.3.1. Questionnaire wording and translation – Translational Bias 
Translation procedures play a central and important role in multilingual survey projects. 
Although good translation products do not assure the success of a survey, badly 
translated questionnaires can ensure that an otherwise sound project fails because the 
poor quality of translation prevents researchers from collecting comparable data.(68) 
Some study limitations were due to the questionnaire itself. The Portuguese 
questionnaire version was translated and adapted by the authors, following pre-test that 
was performed in volunteers in order to understand major drawbacks of the translation 
and possible corrections. Pre-test respondents mentioned that a few statements were 
confusing, these were rewritten to provide an easy understanding of Portuguese version 
and the comparability of the data collected with other studies. 
This questionnaire was adapted from a similar study conducted by The Netherlands 
Pharmacovigilance Centre in patients that have already report an ADR.(47) Comparison 
becomes important to understand the trend that the introduction of the patients in the 
pharmacovigilance system in Portugal, and how these trends can be modified to achieve 
positive results. 
 
5.3.2. Questionnaire administration Bias 
The mode of questionnaire administration is likely to affect the quality and quantity of 
data collected. The data collection process involves an interaction between the 
questionnaire, the respondent and, in case of face-to-face interviews, the interviewer.(69) 
There are many potential influences on responses that can have effect on quality of data 
obtained. Personal face-to-face interview using traditional paper and pencil 
questionnaires (PAPI) were conducted.  
Face-to-face interviews can have potential benefits, like a higher preference for this 
administration mode by respondents, more complete population coverage for sampling, 
high survey response rate, the high completion and item response of the questionnaires 
and finally the amount of information collected.(69) 
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In contrast, the influence of the social setting could cause desirability bias, acquiescence 
bias and interviewer bias that which be considered as major potential negative biases in 
our questionnaire administration mode. Social interaction between the interviewer and 
respondent can lead to respondents taking social norms into account when responding, 
resulting in social desirability bias. Additionally, an interviewer can also cause biases due 
to the reluctance caused in people to reveal beliefs unlikely to be endorsed by the 
interviewer.(69) Question order effects and response-choice order effects does not appear 
to have great influence in face-to-face questionnaires, so they are not considered as 
major biases of our study.(69) 
Specifically in this study, sample selection bias could also be present. Non-randomized 
method of selection of the sample could cause a biased sample, which commonly does 
not have significant value in the extrapolation of the results to the population. Selection 
method might contribute to the exclusion of some drug users’ classes, such as some of 
the oldest patients as suggested by Frisk et al.(67) 
Communication barrier was also a potential bias due to literacy barriers. Interviewer 
efforts to motivate respondents, clarifying questions can lead to interviewer and social 
desirability bias. The burden of patient-HCP relation between interviewer and 
respondents could also affect the data collection, contributing to a high response rate and 
high completion of the questionnaires.  
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6. FINAL REMARKS 
In this chapter, meaning of the study and unanswered questions and future research are 
discussed. The last paragraph gives the conclusions based on this research. 
6.1. MEANING OF THE STUDY  
The aim of the present study was to gain insight into the attitude and behaviour of 
patients in Portugal, with respect to the reporting of ADRs. Our main and additional 
research questions will be answered one by one below. 
 
Which motives for reporting adverse drug reactions are present in a large group of 
patients in Portugal? 
As described in the first paragraph of this chapter, several motives are present: 
- Severity of the reaction 
- Worried about situation 
- Contribution to research and knowledge 
- Contribution to improvement of drugs 
- ADR not mentioned in patient information leaflet 
- Prevent harm to other people 
- The reaction is serious 
 
These motives can be classified in reporting for oneself (severity, worried, problems), 
reporting for others (share experiences, preventing harm, feeling responsible) or 
reporting for improvement (research and knowledge, patient information leaflet). It 
appeared that various patient characteristics (gender, age and level of education) had an 
effect on the motives of patients to report their ADR. 
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What could be the next steps to bring patients to active Pharmacovigilance? 
The development of online form for all countries, and its disclosure by patients will cause 
an increasing in reports. Educational interventions with information disclosure to 
patients, regarding forms and general pharmacovigilance could be one of the measures to 
improve patients’ knowledge and attitudes regarding pharmacovigilance. Regular training 
sessions to promote pharmacovigilance for patients and to address the various perceived 
obstacles to spontaneous reporting are very necessary for a long term improvement of 
ADR reporting and for the active involvement of patients in active Pharmacovigilance. The 
patient-HCP relationship should be encouraged because HCP could play an important role 
in spontaneous reporting system by acting as facilitator and promoting patient’ ADR 
reporting. 
 
6.2. UNANSWERED QUESTIONS AND FURTHER RESEARCH 
The main question which remains unanswered after this study is why patients do not 
report their experienced ADRs. Further work is needed to study a random sample of the 
Portuguese population as a reference-group, to make a comparison with the results 
found. Other Portuguese regions should be taken into account and the possibility of 
educational interventions, starting to patients’ associations that could be a measure to 
spread information among patients. 
Finally, further investigation is needed to gain information on the importance of patient 
reports in signal detection activities, which should be evaluated at a national level, with 
great number of reports. A new strategy to promote spontaneous ADR reporting also 
involves the use of technology as a facilitator of the act of report, including the 
implementation of online reporting, which has the advantage of being quicker to send 
and simpler to complete. 
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6.3. CONCLUSIONS 
Few studies are available about the reasons or motives why patients actually report 
suspected ADRs. Patients had potential to contribute with useful information on drug 
safety, which should be maximized. Because HCPs and patients have different views 
regarding ADR reporting, in daily practice it is important to receive reports from both 
groups to assess the true nature of the ADR. Consumer reporting had already shown 
important and valuable information on drug safety. Despite of this, this contribution can 
be maximized. From these results we hypothesize that the management of ADR 
monitoring is not perfect and need serious rethinking. Lack of knowledge would 
automatically affect reporting, therefore, awareness programs; through educational 
intervention are needed to improve ADR reporting. There is a great need to create 
awareness and to promote the reporting of ADR.  
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APPENDIX I – QUESTIONNAIRE (ENGLISH) 
 
Patient Reporting – Are Patients ready to take part in Pharmacovigilance 
System? – Questionnaire Final Version 
 
According to WHO, spontaneous adverse drug reactions (ADR) reporting is defined by “a regional or country-wide 
system for the reporting of suspected adverse drug reactions”. Thus, this is the primary method in pharmacovigilance 
and it is useful to picking up signals of relatively rare, serious and unexpected adverse reactions. Voluntary ADR 
reporting is one of the most versatile pharmacovigilance systems, because, among other advantages, it covers the 
entire population as well as all medicals drugs throughout their commercial life, being also a free method. 
Section I – Personal Information 
 
Gender 
 Male  
 Female 
 
 
Age Group 
 18-24 Years   
 25-34 Years    
 35-44 Years    
 45-54Years  
 55-64Years 
 65 + Years 
 
 
Highest education Level 
 None 
 Primary 
 Few Years Secundary 
 Secundary Completed 
 High School 
 Bachelor 
 Master 
 Doctorate 
 
 Working Status 
 Full time 
 Part time 
 Not working 
 Retired 
 Studying 
 
 
 
 
I am an healthcare professional: 
 Yes 
 No 
 
 
 
Mestrado em Farmácia – Especialização em Farmacoterapia Aplicada 
  
  
54 
 
Section II– Reporting Knowledge 
 
1) Do you know the Portuguese NPS (National Pharmacovigilance System)? 
 Yes 
 No 
 
2) Did you know that is possible for patients to do a spontaneous reporting of a possible 
ADR? 
 Yes 
 No 
 
Answer YES in the question 2 Answer NO in the question 2 
2.1 - How did you learn about the possibility of doing a reporting of possible 
ADR from medicines? 
 From a GP 
 From a hospital 
 From a pharmacy 
 From a family member or friend 
 From a magazine or newspaper 
 From internet research 
 From INFARMED website 
 I’ve learned at School (Formation) 
 Other_____________________________________ 
 
2.2 – What’s for you the best way to do a report? 
 Directly - Online / By Computer 
 Directly - by post 
 Directly - by telephone 
 Indirectly - throw an HCP 
 
2.3 - Would you recommend to someone to do a spontaneous report about 
an adverse drug reaction? 
 Yes 
 No 
Follow to question 3 
 
 
3) When you a have/if will have a suspected ADR what do you do? (Tick all that apply) 
 Talk with your GP/doctor 
 Talk to your pharmacy 
 Make a spontaneous reporting 
 Stop the medication 
 Don’t do nothing 
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4) Have you ever had side effects from any medicine? 
 Yes 
 No 
 
Answer YES in the question 4 Answer NO in the question 4 
4.1 - If yes, did you report it? 
 Yes 
 No 
4.2 - In the future, if you have any side effects 
will you report? 
 Yes 
 No 
 Not Sure/Don’t know 
 
 
 
Answer YES in the question 4.1 Answer NO in the question 4.1 
4.1.1.1 - Do you think it’s a easy method? 
 Yes 
 No 
 
4.1.1.2 - Did you expect to get any feedback 
(confirmation/scientific explanation) from NPS 
(National Pharmacovigilance System) about 
your report? 
 Yes 
 No 
 
4.1.2.1 - If not, why not? 
 Side effect not serious enough 
 Didn´t realize side effect due to medicine 
 Expected/knew side effect 
 Stopped using medicine 
 Is unnecessary 
 Other (including embarrassed, abroad, 
didn´t read instructions) 
 Don’t know how to report 
 
4.1.2.2 - Do you know the spontaneous report 
patients form? 
 Yes 
 No 
 
Answer YES in the question 4.1.2.2 
4.1.2.2.1 - Do you know how to obtain it? 
 Yes 
 No 
 
 
 
 
 
Mestrado em Farmácia – Especialização em Farmacoterapia Aplicada 
  
  
56 
 
5 - Rate each of the following items, at a five-point Likert scale (strongly agree to strongly 
disagree), where the middle position was labeled ‘neutral’ to reflect a neutral position.  
Reasons to report: 
 SA A N D SD 
I wanted extra information      
The adverse drug reaction was severe       
It was difficult to discuss the adverse drug reaction with my medical practitioner or 
pharmacist  
     
The possibility for reporting an adverse drug reaction just exists       
I wanted to be heard       
Someone else pointed the possibility for reporting an adverse drug reaction      
I was angry about the situation       
I wanted action to be taken       
I wanted to share my experiences       
The adverse drug reaction was not mentioned in the patient information leaflet       
I was worried about my own situation       
 
Opinions to report:  
 SA A N D SD 
Reporting an adverse drug reaction can prevent harm to other people       
I felt responsible for reporting an adverse drug reaction       
Reporting an adverse drug reaction that is already mentioned in the patient 
information leaflet is useless  
     
I only report an adverse drug reaction if it is serious       
Reporting an adverse drug reaction contributes to research and knowledge       
I report an adverse drug reaction if it is not mentioned in the patient information 
leaflet  
     
I benefit from reporting an adverse drug reaction       
Reporting an adverse drug reaction contributes to improvement of drugs       
I report an adverse drug reaction if it is unexpected       
In the future, I will report a possible adverse drug reaction      
 
Adapted from: 
 
 Anderson C, Krska J, Murphy E, Avery A. The importance of direct patient reporting of suspected adverse drug reactions: a patient 
perspective. British journal of clinical pharmacology. 2011;72(5):806-22. 
 van Hunsel F, van der Welle C, Passier A, van Puijenbroek E, van Grootheest K. Motives for reporting adverse drug reactions by 
patient-reporters in the Netherlands. European journal of clinical pharmacology. 2010;66(11):1143-50.  
Mestrado em Farmácia – Especialização em Farmacoterapia Aplicada 
  
  
57 
 
APPENDIX II – QUESTIONÁRIO (PORTUGUÊS) 
 
Patient Reporting – Are Patients ready to take part in Pharmacovigilance 
System? – Versão final do questionário 
 
Segundo a OMS, a notificação espontânea de reacções adversas a medicamentos (RAM) é definida como "um sistema 
regional ou nacional para a notificação de suspeitas de reações adversas a medicamentos". Assim, este é o principal 
método de farmacovigilância e é útil para captar sinais relativamente a reacções adversas graves, raras e 
inesperadas. A notificação voluntária é um dos sistemas de farmacovigilância mais versáteis, porque, entre outras 
vantagens, abrange toda a população, bem como todos os medicamentos durante toda a sua vida comercial, sendo 
também um método praticamente grátis. A informação recolhida neste questionário é anónima e confidencial e 
destina-se a fins meramente académicos, para o estudo em que se insere ou outros estudos futuros dos mesmos 
autores. 
 
Secção I – Informação Pessoal 
 
Género: 
 Masculino 
 Feminino 
 
 
Faixa etária: 
 18-24 Anos   
 25-34 Anos    
 35-44 Anos    
 45-54 Anos  
 55-64 Anos 
 65 + Anos 
 
 
Nível Educacional: 
 Nenhum 
 Escola Primária 
 2º ou 3º Ciclo 
 Secundário não Completo 
 Ensino Secundário 
 Licenciatura 
 Mestrado 
 Doutoramento 
 
Emprego: 
 Tempo Inteiro 
 Part time 
 Desempregado 
 Reformado 
 Estudante 
 
  
 
 
 
Profissional de Saúde 
 Sim 
 Não 
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Secção II– Conhecimento em Farmacovigilância 
 
1) Conhece o Sistema Nacional de Farmacovigilância (SNF)? 
 Sim 
 Não 
 
2) Tem conhecimento da possibilidade de notificar uma reacção adversa a medicamentos 
(RAM) ? 
 Sim 
 Não 
 
Resposta SIM à questão 2 Resposta NÃO à questão 2 
2.1 –Como teve conhecimento acerca da possibilidade de notificar uma 
RAM? 
 Através do meu médico 
 No hospital 
 Na farmácia 
 Através de um familiar ou amigo 
 Num jornal/revista 
 Na internet 
 No website do INFARMED 
 Na escolar (em disciplinas) 
 Outra_____________________________________ 
 
2.2 – Na sua opinião, qual é a melhor maneira para notificar? 
 Diretamente ao SNF - Online (através do computador) 
 Diretamente ao SNF - Por carta/correio 
 Diretamente ao SNF - Por telefone 
 Indiretamente através de um Profissional de Saúde 
 
2.3 – Recomendaria a alguém fazer uma notificação espontânea de uma 
possível reacção adversa? 
 Sim 
 Não 
Seguir para a questão 3 
 
 
3) O que faz quando tem/se tiver uma possível RAM? (Pode assinalar várias opções) 
 Falo com o meu médico de família/especialista 
 Falo com a minha farmácia 
 Faço uma notificação espontânea 
 Paro a medicação 
 Não faço nada 
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4) Alguma vez sentiu alguma reacção adversa a um medicamento? 
 Sim 
 Não 
 
Resposta SIM à questão 4 Resposta NÃO à questão 4 
4.1 – Se sim, notificou? 
 Sim 
 Não 
No futuro, se tiver uma reação adversa a um 
medicamento, irá notificar esse acontecimento? 
 Sim 
 Não 
 
 
 
Resposta SIM à questão 4.1 Resposta NÃO à questão 4.1 
4.1.1.1 – Achou que é um método fácil? 
 Sim 
 Não 
 
4.1.1.2 – Espera obter algum feedback 
(confirmação/explicação científica) do SNF 
sobre a sua notificação? 
 Sim 
 Não 
 
4.1.2.1 – Caso não tenha notificado, porque não o 
fez? 
 A RAM não era séria 
 Não tenho certeza que a RAM tenha sido 
provocada pelo medicamento. 
 A RAM era esperada/conhecida para aquele 
medicamento 
 Parei de utilizar o medicamento 
 Não é necessário notificar 
 Outro (incluindo vergonha, má utilização do 
medicamento/não li as instruções) 
 Não sei como notificar 
 
4.1.2.2 – Conhece o formulário de notificação de 
RAM para pacientes? 
 Sim 
 Não 
 
Resposta SIM à questão 4.1.2.2 
4.1.2.2.1 – Sabe como obter esse formulário? 
 Sim 
 Não 
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5 – Classifique cada um dos seguintes pontos segundo a escala de corcordância apresentada 
(concordo plenamente, corcordo, neutro, discordo, discordo plenamente). O ponto intermédio 
serve para tomar uma posição neutra e não uma incapacidade de responder. 
Razões para notificar (no caso de sofrer uma reacção adversa): 
 CP C N D DP 
Quero informação extra acerca da reacção       
A reação adversa é grave       
É difícil discutir a reação adversa com o meu médico ou farmacêutico       
Tenho vontade de notificar a reação adversa que aconteceu      
Quero ser ouvido      
Alguém me alertou para a possibilidade de notificar uma RAM       
Sinto-me irritado/frustrado com a situação provocada pela RAM       
Quero que sejam tomadas medidas       
Quero compartilhar a minha experiência      
A reacção adversa não está mencionada no folheto informativo      
Estou preocupado com a minha própria situação       
 
Opiniões acerca da notificação:  
 SA A N D SD 
Notificar uma reacção adversa ao medicamento pode evitar danos a outras pessoas       
Sinto-me responsável por notificar uma reacção adversa ao medicamento       
Notificar uma RAM, quando esta está descrita no folheto informativo, é inútil       
Apenas notifico uma reação adversa a medicamentos, se for grave       
Notificar uma RAM contribui para a pesquisa e conhecimento       
Notifico uma RAM, se esta não estiver descrita no folheto informativo      
Eu beneficio se notificar uma reação adversa a medicamento       
Notificar uma reacção adversa a medicamentos contribui para melhorar os medicamentos       
Notifico uma reação adversa a medicamentos, se for inesperada       
No futuro, vou notificar uma possível reação adversa a medicamentos      
 
Adaptado de: 
 
Anderson C, Krska J, Murphy E, Avery A. The importance of direct patient reporting of suspected adverse drug reactions: a patient 
perspective. British journal of clinical pharmacology. 2011;72(5):806-22. 
van Hunsel F, van der Welle C, Passier A, van Puijenbroek E, van Grootheest K. Motives for reporting adverse drug reactions by patient-
reporters in the Netherlands. European journal of clinical pharmacology. 2010;66(11):1143-50. 
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APPENDIX III - CORRELATIONS 
 
 
 
 
 
 
 
